Answers are grounded in this paper and cite their sources.
Background. Nonalcoholic fatty liver disease (NAFLD), the most prevalent chronic liver disorder, is closely linked to metabolic disturbances, with insulin resistance (IR) being a key component. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exhibit pleiotropic metabolic effects; however, data on their efficacy in patients without diabetes mellitus (DM) remain limited and controversial. Aim. To assess the effects of 48-week SGLT2i (dapagliflozin) therapy on the dynamics of liver steatosis, fibrosis, and metabolic/cardiometabolic risk parameters in patients with NAFLD without DM. Materials and Methods. A prospective open-label study included 54 patients with confirmed NAFLD and no diagnosis of DM. Patients were allocated into two comparable groups: the main group (n=26) received dapagliflozin 10 mg/day, and the control group (n=28) received no study-specific treatment during the observation period. At baseline and after 48 weeks, all patients underwent assessment of anthropometric data, key laboratory parameters, and transient elastography (FibroScan®) to measure controlled attenuation parameter (CAP, dB/m) and liver stiffness (LSM, kPa). Statistical analysis employed nonparametric methods. Results. The treatment group demonstrated a statistically significant reduction in liver steatosis (p<0.001) and stiffness (p<0.001). Significant improvements were also noted in IR indices, lipid profile, serum uric acid levels, and transaminase activity. The control group showed an increase in both CAP and LSM (p<0.001). The relative risk for steatosis regression with therapy was 5.2 (95% CI 2.3–11.5) and for fibrosis regression 13.4 (95% CI 3.5–51.3). Regression analysis identified an association between steatosis regression and reduced waist circumference, and between fibrosis regression and decreased body mass index and uric acid levels. Conclusion. Forty-eight-week dapagliflozin therapy was associated with significant regression of liver steatosis and fibrosis, as well as improved metabolic status in patients with NAFLD without concomitant DM. These findings support the potential of SGLT2i as a promising pathogenetic treatment option for NAFLD, warranting further investigation.
No takes yet. Share an insight, caveat, or question.
Ивановна et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: